A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.

Also called NCT03724981

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 312 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03724981
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03724981. Randomized; no masking; primary purpose other. Start 2018-10-18 (actual); primary completion 2019-04-12 (actual). Results posted on 2020-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dulaglutide Pen
Intervention (Drug)
Semaglutide Pen
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03724981
Content hash
cde0df80a73ad889e6c7094b5ab2036f1c21362030ddaf2eb8bd5eeab3928058